To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Laboratory | Chemistry | High-throughput screening | CBRN-E threats | Pharmacology
Research themes revolve around organic synthesis and medicinal chemistry. After identifying bioactive compounds by high-throughput screening, the team can take charge of their chemical optimization (structure/function relationship study) either to improve the initial activity or to increase the solubility. In the case of phenotypic screens (cellular screening for which the target is not known), the team can also manage the design and synthesis of probes for the identification of the target. Mainly based on target-fishing approaches via photoactivable radiolabeled probes, this approach can also be coupled to "click chemistry" to use affinity techniques to identify these targets. The team also contributes to the national chemical library through the provision of an internal chemical library for the unit.
As part of the research and development program CBRN-E and in collaboration with the Daniel Gillet's group (SIMOPRO), we identified by high throughput screening three compounds capable of blocking the deleterious action of two toxins (ricin and Shiga toxin) on human cells. By chemical optimization, we were able to increase up to a factor of 1000 the initial activity of one of the hits obtained from the screening. These molecules, which act by blocking the toxin retrograde transport and not directly on the toxin, also showed activity against other pathogens using the same traffic pathway in the cell (such as parasites). The elucidation of the mode of action of these compounds is in progress.
The team is also part of the LERMIT LabEx and as such engaged in two projects, one to identify by high throughput screening new antibacterial compounds, the second in the field of anticancer molecules.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.